Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Australia's Therapeutic Goods Administration (TGA) recently issued a safety alert requiring extra warnings to be included ...

While antipsychotics can be effective for some patients, they come with well-known side effects, including an increased risk ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with ...

Part of you is concerned — after all, you know depression can be serious — but on the other hand, can’t weight loss be a good ...

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...

Johnson & Johnson (JNJ) stock in focus as FDA expands the label for its depression therapy Spravato (esketamine) allowing its ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).